CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults

The purpose of this phase I/II clinical trial is to test CARCIK-CD123/33 cells to treat patients with R/R AML/BPDCN, who have otherwise exhausted conventional treatment options. In particular, this study will assess the safety and feasibility of CARCIK-CD123/33 cells infusion in adults and children with R/R AML, ahead of scheduled alloHCT.

Trial Details

NCT ID

NCT07877610

Phase

PHASE1 / PHASE2

Sponsor

Fondazione Matilde Tettamanti Menotti De Marchi Onlus

Status

RECRUITING

Cancer Type

Leukemia

Interventions

CARCIK CD123/33 infusion

Locations (sample)

Monza, MB, Italy|45.58005,9.27246
Bergamo, Italy|45.69601,9.66721

Key Eligibility Criteria

Patients/ parents or legal representatives able and willing to provide written informed consent and to comply with the study protocol according to …
Age limits: children (6 months - 17 years old) and adults (≥18 years old - 75 years old)
Subjects with active AML/BPDCN with evidence of tumor involvement in the bone marrow and/or peripheral blood as determined by morphology and flow c…
AML/ BPDCN that has not achieved a CR, CRh, CRi, MLFS ELN criteria (1); partial remission or refractory disease (including primary refractory) afte…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →